Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 22 2021 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of November, 2021
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
BiondVax Pharmaceuticals Ltd. (hereinafter, the
“Registrant”, the “Company”, or “BiondVax”) hereby furnishes
the following documents in connection with its Annual General Meeting of Shareholders scheduled for December
27, 2021 at 4:00 p.m. Israel time at the offices of Gross & Co., One Azrieli Center, Tel Aviv 6701101, Israel:
|
(1)
|
Notice
and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders to
be held on December 27, 2021, describing the proposals to be voted upon at the meeting, the
procedure for voting in person or by proxy at the meeting and various other details related
to the meeting; and
|
|
(2)
|
Proxy Card whereby holders of Company shares may vote at the meeting
without attending in person.
|
The Notice and Proxy Statement is furnished with
this Form 6-K as Exhibit 99.1 and the Proxy Card is furnished with this Form 6-K as Exhibit 99.2.
Exhibit Index
Exhibits 99.1 and 99.2 of this Report on Form 6-K are hereby incorporated
by reference into the Company’s Registration Statement on Form S-8 (Registration No. 333-239344) and its Registration Statement
on Form F-3 (Registration No. 333-240189).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: November 22, 2021
|
By:
|
/s/ Amir Reichman
|
|
|
Amir Reichman
|
|
|
Chief Executive Officer
|
2
Biovaxys Technology (QB) (USOTC:BVAXF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Biovaxys Technology (QB) (USOTC:BVAXF)
Historical Stock Chart
From Aug 2023 to Aug 2024